Loading clinical trials...
Loading clinical trials...
This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with an anticholinergic.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Urologic Clinics of North Alabama
Huntsville, Alabama, United States
Alaska Urological Institute dba Alaska Clinical Research Center
Anchorage, Alaska, United States
South Orange County Medical Research Center
Laguna Hills, California, United States
University of Southern California
Los Angeles, California, United States
Genesis Research LLC
San Diego, California, United States
U. Colorado, School of Med.
Aurora, Colorado, United States
Genitourinary Surgical Consultants
Denver, Colorado, United States
Urology Associates of Norwalk
Norwalk, Connecticut, United States
Sunrise Medical Research
Lauderdale Lakes, Florida, United States
Bladder and Prostate Health Investigations, LLC
Miramar, Florida, United States
Start Date
October 28, 2013
Primary Completion Date
May 24, 2016
Completion Date
January 5, 2017
Last Updated
November 6, 2017
254
ACTUAL participants
onabotulinumtoxinA
BIOLOGICAL
Normal saline
DRUG
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07195656